



PRIOR AUTHORIZATION POLICY

- POLICY:** Tasimelteon Products Prior Authorization Policy
- Hetlioz™ (tasimelteon capsules – Vanda, generic)
 - Hetlioz LQ™ (tasimelteon oral suspension – Vanda)

REVIEW DATE: 01/28/2026

INSTRUCTIONS FOR USE

THE FOLLOWING COVERAGE POLICY APPLIES TO HEALTH BENEFIT PLANS ADMINISTERED BY CIGNA COMPANIES. CERTAIN CIGNA COMPANIES AND/OR LINES OF BUSINESS ONLY PROVIDE UTILIZATION REVIEW SERVICES TO CLIENTS AND DO NOT MAKE COVERAGE DETERMINATIONS. REFERENCES TO STANDARD BENEFIT PLAN LANGUAGE AND COVERAGE DETERMINATIONS DO NOT APPLY TO THOSE CLIENTS. COVERAGE POLICIES ARE INTENDED TO PROVIDE GUIDANCE IN INTERPRETING CERTAIN STANDARD BENEFIT PLANS ADMINISTERED BY CIGNA COMPANIES. PLEASE NOTE, THE TERMS OF A CUSTOMER'S PARTICULAR BENEFIT PLAN DOCUMENT [GROUP SERVICE AGREEMENT, EVIDENCE OF COVERAGE, CERTIFICATE OF COVERAGE, SUMMARY PLAN DESCRIPTION (SPD) OR SIMILAR PLAN DOCUMENT] MAY DIFFER SIGNIFICANTLY FROM THE STANDARD BENEFIT PLANS UPON WHICH THESE COVERAGE POLICIES ARE BASED. FOR EXAMPLE, A CUSTOMER'S BENEFIT PLAN DOCUMENT MAY CONTAIN A SPECIFIC EXCLUSION RELATED TO A TOPIC ADDRESSED IN A COVERAGE POLICY. IN THE EVENT OF A CONFLICT, A CUSTOMER'S BENEFIT PLAN DOCUMENT ALWAYS SUPERSEDES THE INFORMATION IN THE COVERAGE POLICIES. IN THE ABSENCE OF A CONTROLLING FEDERAL OR STATE COVERAGE MANDATE, BENEFITS ARE ULTIMATELY DETERMINED BY THE TERMS OF THE APPLICABLE BENEFIT PLAN DOCUMENT. COVERAGE DETERMINATIONS IN EACH SPECIFIC INSTANCE REQUIRE CONSIDERATION OF 1) THE TERMS OF THE APPLICABLE BENEFIT PLAN DOCUMENT IN EFFECT ON THE DATE OF SERVICE; 2) ANY APPLICABLE LAWS/REGULATIONS; 3) ANY RELEVANT COLLATERAL SOURCE MATERIALS INCLUDING COVERAGE POLICIES AND; 4) THE SPECIFIC FACTS OF THE PARTICULAR SITUATION. EACH COVERAGE REQUEST SHOULD BE REVIEWED ON ITS OWN MERITS. MEDICAL DIRECTORS ARE EXPECTED TO EXERCISE CLINICAL JUDGMENT WHERE APPROPRIATE AND HAVE DISCRETION IN MAKING INDIVIDUAL COVERAGE DETERMINATIONS. WHERE COVERAGE FOR CARE OR SERVICES DOES NOT DEPEND ON SPECIFIC CIRCUMSTANCES, REIMBURSEMENT WILL ONLY BE PROVIDED IF A REQUESTED SERVICE(S) IS SUBMITTED IN ACCORDANCE WITH THE RELEVANT CRITERIA OUTLINED IN THE APPLICABLE COVERAGE POLICY, INCLUDING COVERED DIAGNOSIS AND/OR PROCEDURE CODE(S). REIMBURSEMENT IS NOT ALLOWED FOR SERVICES WHEN BILLED FOR CONDITIONS OR DIAGNOSES THAT ARE NOT COVERED UNDER THIS COVERAGE POLICY (SEE "CODING INFORMATION" BELOW). WHEN BILLING, PROVIDERS MUST USE THE MOST APPROPRIATE CODES AS OF THE EFFECTIVE DATE OF THE SUBMISSION. CLAIMS SUBMITTED FOR SERVICES THAT ARE NOT ACCOMPANIED BY COVERED CODE(S) UNDER THE APPLICABLE COVERAGE POLICY WILL BE DENIED AS NOT COVERED. COVERAGE POLICIES RELATE EXCLUSIVELY TO THE ADMINISTRATION OF HEALTH BENEFIT PLANS. COVERAGE POLICIES ARE NOT RECOMMENDATIONS FOR TREATMENT AND SHOULD NEVER BE USED AS TREATMENT GUIDELINES. IN CERTAIN MARKETS, DELEGATED VENDOR GUIDELINES MAY BE USED TO SUPPORT MEDICAL NECESSITY AND OTHER COVERAGE DETERMINATIONS.

CIGNA NATIONAL FORMULARY COVERAGE:

OVERVIEW

Tasimelteon products are melatonin receptor agonists indicated for the following uses:^{1,2}

- Tasimelteon capsule is indicated for the treatment of:
 - **Non-24-Hour Sleep-Wake Disorder (Non-24)** in adults.
 - **Nighttime Sleep Disturbances in Smith-Magenis Syndrome (SMS)**, in patients ≥ 16 years of age.
- Hetlioz LQ is indicated for the treatment of **nighttime sleep disturbances in SMS**, in patients 3 to 15 years of age.

Disease Overview

Non-24 is a chronic circadian rhythm disorder that is due to the misalignment of the endogenous master body clock to the 24-hour day which disrupts the sleep-wake cycle. Patients who are completely blind are particularly susceptible to this

condition; as many as one-half to three-quarters of totally blind patients have Non-24, which is approximately 65,000 to 95,000 Americans.³⁻⁸ Patients can be diagnosed using circadian phase markers (e.g., measurement of urinary melatonin levels, dim light melatonin onset [assessed in blood or saliva], or assessing core body temperature).^{3,8,9} Alternative forms of diagnosis include actigraphy and assessment of sleep logs (sleep diaries).^{3,8,9} Actigraphy is a non-invasive method of monitoring human rest and activity cycles and involves the use of a portable device to document movement. Other reviews confirm these diagnostic methods.^{8,9}

SMS is a rare disorder identified by an array of physical, neurobehavioral, and developmental characteristics.¹⁰ In the United States, the incidence is estimated to be 1 in 15,000 to 25,000 people in the general population. Cases of SMS are predominantly related to either a deletion or mutation in the *RAI1* gene. Sleep disturbances start as early as one year of age and continue into adulthood and include shortened sleep cycles with multiple awakenings during the night, early morning arousal from sleep, and increased somnolence during daytime hours. Inability to achieve a normal sleeping pattern appears to aggravate behavioral issues such as impulsivity, aggression, hyperactivity and frequent temper tantrums. Sleep issues in SMS have been attributed to a primary disturbance of the circadian clock disruption and instabilities in melatonin secretion. Physical traits such as muscle weakness, obesity-related breathing difficulties, and facial composition can be underlying factors that affect sleep.

Clinical Efficacy

The efficacy of Hetlioz for Non-24 was established in two Phase III pivotal studies involving totally blind patients with Non-24 who reported no light perception for up to 6 months and evaluated the effects of Hetlioz withdrawal.^{1,3} In the Hetlioz group, 29% of patients (n = 12) met responder criteria, defined as patients with both a ≥ 45 minute increase in nighttime sleep and a ≥ 45 minute decrease in daytime nap time, compared with 12% of patients (n = 5) who received placebo (time of endpoint assessment was not stated).¹ During the withdrawal period of the trial, which lasted 8 weeks, 90% of patients who continued Hetlioz (n = 9/10) remained entrained (circadian rhythm synchronized to 24-hour day) compared with 20% of patients randomized to receive placebo (n = 2/10).^{3,4}

The data for Hetlioz and Hetlioz LQ supporting benefits for nighttime sleep disturbances in SMS are underwhelming.^{1,11} The pivotal trial for SMS included very few patients and was relatively short-term; this condition would likely require long-term therapy. Only one of the two primary efficacy endpoints was statistically significant after controlling for multiple comparisons.

Guidelines

In 2015, clinical practice guidelines were published by the American Academy of Sleep Medicine that address Non-24.⁶ The condition mainly occurs in patients who are blind. The Task Force states that there is no evidence to support the use of sleep-promoting medications in patients with Non-24. Data suggest that melatonin entrainment occurs with melatonin at a greater rate than placebo and melatonin can be an effective treatment for Non-24. The Task Force recommendation was

that clinicians use strategically timed melatonin for the treatment of Non-24 in adults who are blind (versus no treatment). There are insufficient data to support use of melatonin among sighted patients with Non-24 (versus no treatment).

The Parents and Researchers Interested in SMS (PRISMS) [2018] created medical management guidelines for the diagnosis, treatment of manifestations, and ongoing surveillance of SMS.¹² The guidelines do not address Hetlioz/Hetlioz LQ. Multidisciplinary treatment is recommended. The guidelines recognize sleep management is a challenge and no well-controlled treatment trials have been reported. The first suggestion is to incorporate a good sleep routine (e.g., consistent bedtime and bedtime routine, quiet/non-stimulating activities, use of white noise or a rhythmic sound, and a comfortably cool/dark room). Concerns for sleep apnea should be addressed. Melatonin is endorsed as monotherapy for sleep management. The concomitant use of a morning beta-blocker (acebutolol) with an evening dose of melatonin for 6 to 8 weeks could be beneficial to restore circadian plasma melatonin rhythmicity, decrease daytime sleepiness, improve daytime behavior, and enhance sleep in children with SMS.

POLICY STATEMENT

Prior Authorization is recommended for prescription benefit coverage of tasimelteon capsules. All approvals are provided for the duration noted below. In cases where the approval is authorized in months, 1 month is equal to 30 days. Because of the specialized skills required for evaluation and diagnosis of patients treated with tasimelteon capsules as well as the monitoring required for adverse events and long-term efficacy, approval requires tasimelteon capsules to be prescribed by or in consultation with a physician who specializes in the condition being treated.

Due to insufficient clinical efficacy data for its FDA-approved use, **approval is not recommended** for Hetlioz LQ.

I. Tasimelteon capsule (Hetlioz, generic) is(are) covered as medically necessary when the following criteria is(are) met for FDA-approved indication(s) or other uses with supportive evidence (if applicable):

FDA-Approved Indication

1. Non-24-Hour Sleep-Wake Disorder (Non-24). Approve for the duration noted if the patient meets ONE of the following (A or B):

A) Initial Therapy. Approve for 6 months if the patient meets ALL of the following (i, ii, iii, iv, and v):

i. Patient is \geq 18 years of age; AND

ii. Patient is totally blind with no perception of light; AND

iii. Diagnosis of Non-24 is confirmed by meeting ONE of the following (a or b):

a) Assessment of at least one physiologic circadian phase marker; OR

Note: Examples of physiologic circadian phase markers include measurement of urinary melatonin levels, dim light melatonin onset (as measured in blood or saliva), and assessment of core body temperature.

- b)** If assessment of at least one physiologic circadian phase marker cannot be done, the diagnosis must be confirmed by actigraphy performed for ≥ 1 week plus evaluation of sleep logs recorded for ≥ 1 month; AND
- iv.** Patient meets BOTH of the following (a and b):
 - a)** Patient has received at least 6 months of continuous therapy (i.e., 6 consecutive months of daily treatment) with melatonin under the guidance of a physician who specializes in the treatment of sleep disorders; AND
 - b)** According to the prescriber, patient had inadequate efficacy with melatonin therapy; AND
Note: Examples of efficacy with melatonin therapy include entrainment, clinically meaningful or significant increases in nighttime sleep, and clinically meaningful or significant decreases in daytime sleep.
- v.** The medication is prescribed by or in consultation with a physician who specializes in the treatment of sleep disorders; OR
- B) Patient is Currently Receiving Tasimelteon Capsules.** Approve for 1 year if the patient meets ALL of the following (i, ii, iii, iv, and v):
 - i.** Patient is ≥ 18 years of age; AND
 - ii.** Patient is totally blind with no perception of light; AND
 - iii.** Patient meets BOTH of the following (a and b):
 - a)** Patient has received at least 6 months of continuous therapy (i.e., 6 consecutive months of daily treatment) with melatonin under the guidance of a physician who specializes in the treatment of sleep disorders; AND
 - b)** According to the prescriber, patient had inadequate efficacy with melatonin therapy; AND
Note: Examples of efficacy with melatonin therapy include entrainment, clinically meaningful or significant increases in nighttime sleep, and clinically meaningful or significant decreases in daytime sleep.
 - iv.** Patient meets BOTH of the following (a and b):
 - a)** Patient has received at least 6 months of continuous therapy (i.e., 6 consecutive months of daily treatment) with tasimelteon capsules under the guidance of a physician who specializes in the treatment of sleep disorders; AND
Note: A patient who has not received at least 6 months of continuous tasimelteon capsules therapy, or if the therapy has not been continuous (i.e., 6 consecutive months of daily treatment), should follow criterion 1A (initial therapy).
 - b)** According to the prescriber, patient has achieved adequate results with tasimelteon capsules therapy; AND

Note: Examples of adequate results with tasimelteon capsules therapy include entrainment, clinically meaningful or significant increases in nighttime sleep, clinically meaningful or significant decreases in daytime sleep.

- v. The medication is prescribed by or in consultation with a physician who specializes in the treatment of sleep disorders.

II. Hetlioz LQ. Due to insufficient clinical efficacy data for its FDA-approved use, approval is not recommended for Hetlioz LQ.

CONDITIONS NOT COVERED

- **Hetlioz™ (tasimelteon capsules - Vanda, generic)**
- **Hetlioz LQ™ (tasimelteon oral suspension – Vanda)**

is(are) considered not medically necessary for ANY other use(s) including the following (this list may not be all inclusive; criteria will be updated as new published data are available):

- 1. Insomnia, Primary.** American Academy of Sleep Medicine guidelines for pharmacologic treatment of chronic insomnia in adults were updated in 2017 and do not address tasimelteon; many other agents are available.¹³ Only limited data have investigated use of tasimelteon capsules in patients with primary insomnia.^{14,15} Further data are needed to establish the safety and efficacy of tasimelteon capsules.
- 2. Nighttime Sleep Disturbances in Smith-Magenis Syndrome (SMS).** Efficacy data for tasimelteon capsules/Hetlioz LQ supporting benefits for nighttime sleep disturbances in SMS are underwhelming.^{1,11}
- 3. Ramelteon Tablets (Rozerem®, generic), Concomitant Therapy.** Ramelteon, a melatonin receptor agonist, is indicated for the treatment of insomnia characterized by difficulty with sleep onset.¹⁶ The safety and efficacy of concomitant use of ramelteon tablets and tasimelteon capsules have not been studied and it is suspected that the adverse events with use of these agents with a similar mechanism of action taken together may be additive (e.g., central nervous system effects [somnolence], hepatic impairment). Ramelteon has not been studied in Non-24. In the clinical trials with tasimelteon capsules, patients were not permitted to use medications that could interfere with the assessment of circadian rhythms.¹⁷
- 4. Sedative Hypnotic Medications or Other Medications for Insomnia or Other Sleep-Related Disorders, Concomitant Therapy.** There are no data to support the safety and efficacy of hypnotic medications in patients with Non-24.⁶ Also, there are no data to determine the safety and efficacy of tasimelteon capsules when used with other sedative hypnotic medications or other medications for insomnia or sleep-related disorders.¹⁸

Note: Examples include benzodiazepines (triazolam, temazepam), nonbenzodiazepine hypnotics (e.g., zolpidem, zaleplon), chloral hydrate.

5. Sleep-Related Disorders, Other Types. A published investigation details a Phase II study (n = 29) and a Phase III study (n = 411) assessing tasimelteon capsules treatment in adults with transient insomnia associated with shifted sleep and wake time.¹⁷ Further studies are needed to establish the efficacy and safety of tasimelteon capsules in patients with other types of sleep-related disorders.

Note: Examples include shift work disorder, jet lag disorder, advanced sleep phase disorder, delayed sleep phase disorder, irregular sleep-wake rhythm disorder.

REFERENCES

1. Hetlioz/Hetlioz LQ™ capsules/suspension [prescribing information]. Washington, DC: Vanda; January 2024.
2. Tasimelteon capsules [prescribing information]. Parsippany, NJ: Teva; December 2022.
3. Lockley SW, Dressman MA, Licanele L, et al. Tasimelteon for non-24-hour sleep-wake disorder in totally blind people (SET and RESET): two multicenter, randomized, double-masked, placebo-controlled phase 3 trials. *Lancet*. 2015;386:1754-1764.
4. Keating GM. Tasimelteon: A Review in Non-24-Hour Sleep-Wake Disorder in Totally Blind Individuals. *CNS Drugs*. 2016 May;30(5):461-8.
5. American Academy of Sleep Medicine. International Classification of sleep disorders: diagnostic and coding manual. 3rd edition. Darien (IL): American Academy of Sleep Medicine; 2014.
6. Auger RR, Burgess HJ, Emens JS, et al. Clinical practice guideline for the treatment of intrinsic circadian rhythm sleep-wake disorders: Advanced Sleep-Wake Phase Disorder (ASWPD), Delayed Sleep-Wake Phase Disorder (DSWPD), Non-24-Hour Sleep-Wake Rhythm Disorder (N24SWD), and Irregular Sleep-Wake Rhythm Disorder (ISWRD). An update for 2015. *J Clin Sleep Med*. 2015;11(10):1199-1236. Available at: <http://www.aasmnet.org/Resources/clinicalguidelines/CRSWD-intrinsic.pdf> Accessed on January 20, 2026.
7. National Sleep Foundation [Internet]. Non-24-hour Sleep Wake Disorder Facts and Prevalence. Updated November 16, 2023. Available at: <https://www.sleepfoundation.org/non-24-sleep-wake-disorder>. Accessed on January 20, 2026.
8. Uchiyama M, Lockley SW. Non-24-Hour Sleep-Wake Rhythm Disorder in Sighted and Blind Patients. *Sleep Med Clin*. 2015;10:495-516.
9. Smith MT, McCrea CS, Cheung J, et al. Use of Actigraphy for the Evaluation of Sleep Disorders and Circadian Rhythm Sleep-Wake Disorders: An American Academy of Sleep Medicine Clinical Practice Guideline. *J Clin Sleep Med*. 2018;14(7):1231-1237. Available at: <https://jcsm.aasm.org/doi/pdf/10.5664/jcsm.7230>. Accessed on January 20, 2026.
10. National Organization for Rare Disorders (NORD). Smith Magenis Syndrome. Updated November 19, 2024. Available at: <https://rarediseases.org/rare-diseases/smith-magenis-syndrome/>. Accessed on: January 20, 2026.
11. Polymeropoulos CM, Brooks J, Czeisler EL, et al. Tasimelteon safely and effectively improves sleep in Smith-Magenis syndrome: a double-blind randomized trial followed by an open-label extension. *Genet Med*. 2021 Dec;23(12):2426-2432.
12. The PRISMS Professional Advisory Board medical management guidelines for an individual diagnosed with SMS. © 2018 Parents and Researchers Interested in Smith-Magenis Syndrome, Inc. Available at: <https://www.prisms.org/about-sms/living-with-sms/medical-management-guidelines/>. Accessed on January 20, 2026.
13. Sateia JM, Buysse DJ, Krystal AD, et al. Clinical practice guideline for the pharmacologic treatment of chronic insomnia in adults: an American Academy of Sleep Medicine Clinical Practice Guideline. *J Clin Sleep Med*. 2017;13(2):307-349. Available at: <https://jcsm.aasm.org/doi/105664/jcsm.6470>. Accessed on January 20, 2026.
14. Feeney J, Birznieks G, Scott C, et al. Melatonin agonist tasimelteon improves sleep in primary insomnia characterized by difficulty falling asleep. *Sleep*. 2009;32(Suppl):43.

15. Synnott NC, Polymeropoulos CM, Xiao C, et al. Melatonin agonist tasimelteon (Hetlioz®) improves sleep in patients with primary insomnia: a multicenter, randomized, double-blind, placebo-controlled trial. *PLoS One*. 2025 Sep 19;20(9):e0332366.
16. Rozerem® tablets [prescribing information]. Deerfield, IL: Takeda; June 2025.
17. Rajartnam SMW, Polymeropoulos MH, Fisher DM, et al. Melatonin agonist tasimelteon (VEC-162) for transient insomnia after sleep-time shift: two randomized controlled multicenter trials. *Lancet*. 2009;373:482-491.
18. No authors listed. Drugs for insomnia. *Treat Guidel Med Lett*. 2012;10(119):57-60.

HISTORY

Type of Revision	Summary of Changes	Review Date
Annual Revision	No criteria changes.	01/17/2024
Annual Revision	No criteria changes.	01/15/2025
Annual Revision	<p>Sedative Hypnotic Medications or Other Medications for Insomnia or Other Sleep-Related Disorders, Concomitant Therapy: In this Condition Not Recommended for Approval, examples of applicable medications were moved to a Note.</p> <p>Sleep-Related Disorders, Other Types: In this Condition Not Recommended for Approval, examples of applicable disorders were moved to a Note.</p>	01/28/2026

"Cigna Companies" refers to operating subsidiaries of The Cigna Group. All products and services are provided exclusively by or through such operating subsidiaries, including Cigna Health and Life Insurance Company, Connecticut General Life Insurance Company, Evernorth Behavioral Health, Inc., Cigna Health Management, Inc., and HMO or service company subsidiaries of The Cigna Group. © 2026 The Cigna Group.